Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Targeting transcription factors for cancer gene therapy.

Libermann TA, Zerbini LF.

Curr Gene Ther. 2006 Feb;6(1):17-33. Review.

PMID:
16475943
2.

ETS transcription factors and their emerging roles in human cancer.

Seth A, Watson DK.

Eur J Cancer. 2005 Nov;41(16):2462-78. Epub 2005 Oct 6. Review.

PMID:
16213704
3.

Report of a meeting: molecular basis of cancer therapy.

Gottesman MM.

J Natl Cancer Inst. 1994 Sep 7;86(17):1277-85.

PMID:
7914937
4.

ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.

Turner DP, Watson DK.

Expert Rev Anticancer Ther. 2008 Jan;8(1):33-42. Review.

PMID:
18095881
5.

ETS transcription factors: possible targets for cancer therapy.

Oikawa T.

Cancer Sci. 2004 Aug;95(8):626-33. Review.

7.

Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

Nikitakis NG, Siavash H, Sauk JJ.

Curr Cancer Drug Targets. 2004 Dec;4(8):637-51. Review.

PMID:
15578920
8.

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Review.

PMID:
18718806
10.

Transcription factors as drug targets in cancer.

Hurst HC.

Eur J Cancer. 1996 Oct;32A(11):1857-63. Review.

PMID:
8943667
11.

The transcription factor ETS-1: its role in tumour development and strategies for its inhibition.

Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N.

Mini Rev Med Chem. 2008 Oct;8(11):1095-105. Review.

PMID:
18855726
12.

Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(3):173-90. Review.

PMID:
15952871
13.

Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.

Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM.

Carcinogenesis. 2006 Oct;27(10):1980-90. Epub 2006 Apr 10.

PMID:
16606632
14.

Nuclear factor-kappaB in development, prevention, and therapy of cancer.

Van Waes C.

Clin Cancer Res. 2007 Feb 15;13(4):1076-82. Review.

15.

A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects.

Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, Yang B, Wang H, Wang Z.

Mol Pharmacol. 2006 Nov;70(5):1621-9. Epub 2006 Aug 25.

16.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
17.

Oncogenes as novel targets for cancer therapy (part III): transcription factors.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(5):327-38. Review.

PMID:
16196502
18.

Defining ETS transcription regulatory networks and their contribution to breast cancer progression.

Turner DP, Findlay VJ, Moussa O, Watson DK.

J Cell Biochem. 2007 Oct 15;102(3):549-59. Review.

PMID:
17661355
19.

Transcriptional anti-angiogenesis therapy of human pancreatic cancer.

Xie K, Wei D, Huang S.

Cytokine Growth Factor Rev. 2006 Jun;17(3):147-56. Epub 2006 Mar 3. Review.

PMID:
16516532
20.

Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(4):247-57. Review.

PMID:
16078861

Supplemental Content

Support Center